Bucindolol

Bucindolol is a non-selective beta blocker with additional weak alpha-blocking properties and some intrinsic sympathomimetic activity.[1][2] It was under review by the FDA in the United States for the treatment of heart failure in 2009, but was rejected due to issues pertaining to integrity of data submitted.[1][3] See also Beta blocker Primidolol References .mw-parser-output .reflist{font-size:90%;margin-bottom:0.5em;list-s... [wikipedia]